Myriad Genetics Balance Sheet Health
Financial Health criteria checks 4/6
Myriad Genetics has a total shareholder equity of $731.7M and total debt of $39.0M, which brings its debt-to-equity ratio to 5.3%. Its total assets and total liabilities are $1.1B and $349.6M respectively.
Key information
5.3%
Debt to equity ratio
US$39.00m
Debt
| Interest coverage ratio | n/a |
| Cash | US$99.90m |
| Equity | US$731.70m |
| Total liabilities | US$349.60m |
| Total assets | US$1.08b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: MYD's short term assets ($293.2M) exceed its short term liabilities ($154.3M).
Long Term Liabilities: MYD's short term assets ($293.2M) exceed its long term liabilities ($195.3M).
Debt to Equity History and Analysis
Debt Level: MYD has more cash than its total debt.
Reducing Debt: MYD's debt to equity ratio has reduced from 20.9% to 5.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MYD has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MYD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.